Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA036873 in Advanced Solid Tumors and Hematological Malignancies
NCT07195916Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Modality
- Bispecific Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of INCA036873 in clear cell renal cell carcinoma (ccRCC), diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) and 2 more (3 arms), sponsored by Incyte. Primary endpoints: Occurrence of Dose Limiting Toxicities and Number of Participants With Treatment Emergent Adverse Events. Started Jan 2026; status: recruiting.
02
Drugs
INCA036873
03
Conditions
clear cell renal cell carcinoma (ccRCC)diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07195916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195916.